
    
      A randomized, open, single-dose, 3 period partial replicated crossover-design clinical trial
      to evaluate the safety and pharmacokinetic characteristics after administration of CKD-333 or
      co-administration of CKD-330 and D085 in healthy volunteers under fasting conditions
    
  